| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5598458 | Annals of Vascular Surgery | 2016 | 22 Pages |
Abstract
In an experienced vascular center in China, although the 30-day mortality and midterm survival of RAAAs were not significantly different between the EVAR and OSR groups, EVAR has superior perioperative advantages. Consequently, EVAR is recommended as the first-line treatment for anatomically suitable RAAA.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Baolei Guo, Zhihui Dong, Weiguo Fu, Daqiao Guo, Xin Xu, Bin Chen, Junhao Jiang, Zhenyu Shi,